MDSpire - Summary
From the Journals

Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction

Extended-release anesthetic did not significantly improve postoperative pain, raising questions about its routine use in dental surgery.

Share

A systematic review and meta-analysis led by Dr. Mohammed Aljumaiaan evaluated the efficacy of liposomal bupivacaine in third molar extraction pain management, revealing it offers minimal clinical benefits despite a slight reduction in opioid use. The analysis, which included 858 participants, found no significant improvement in postoperative pain intensity or cumulative pain scores when compared to standard bupivacaine or placebo. The authors stressed the need for further research, suggesting existing costs may not justify routine use in this context.

Original Source(s)

Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction

  • by Olivia Anderson

  • March 25, 2026

Related Content

Q&A: What are your ethical obligations if another dentist dies before completing treatment?

A recent news report described financial challenges faced by patients who had prepaid for treatment before their dentist unexpectedly died.

Lobby Day 2026 delivers strong impact

Approximately 500 dentists and dental students gathered in Washington, D.C., for Lobby Day 2026.

ADA adds mental health, GLP-1 questions to health history forms

The updated forms became available for purchase through the ADA Store on March 24.